On October 15, pharmaceutical company Lilly announced the establishment of the China Medical Innovation Center in Beijing and plans to introduce the innovation incubator Lilly Gateway Labs. The new center will work to improve the efficiency of clinical trials and accelerate drug registration reviews in order to bring new drugs to patients more quickly. At the same time, LGL will support early-stage domestic biotechnology companies and promote scientific innovation. Eli Lilly said that this move will strengthen its business layout in the Chinese market and is expected to bring new opportunities for medical innovation and drug development in China, and help achieve the “Healthy China 2030” goal.

Zhitongcaijing · 10/15 11:33
On October 15, pharmaceutical company Lilly announced the establishment of the China Medical Innovation Center in Beijing and plans to introduce the innovation incubator Lilly Gateway Labs. The new center will work to improve the efficiency of clinical trials and accelerate drug registration reviews in order to bring new drugs to patients more quickly. At the same time, LGL will support early-stage domestic biotechnology companies and promote scientific innovation. Eli Lilly said that this move will strengthen its business layout in the Chinese market and is expected to bring new opportunities for medical innovation and drug development in China, and help achieve the “Healthy China 2030” goal.